These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36939504)

  • 1. Regression of perianal warts after nonavalent human papillomavirus vaccination.
    Dianzani C; Neagu N; Venuti A; Coscarella G; DE Franciscis B; Montini F; Zalaudek I; Conforti C
    Ital J Dermatol Venerol; 2023 Feb; 158(1):62-63. PubMed ID: 36939504
    [No Abstract]   [Full Text] [Related]  

  • 2. Nonavalent human papillomavirus vaccination as alternative treatment for genital warts.
    Bossart S; Gabutti MP; Seyed Jafari SM; Hunger RE
    Dermatol Ther; 2020 Jul; 33(4):e13771. PubMed ID: 32500585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HPV vaccination with quadrivalent or nonavalent vaccine: an opportunity to eliminate genital warts as well].
    van Bergen JEAM
    Ned Tijdschr Geneeskd; 2020 Jan; 164():. PubMed ID: 32073799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real world effectiveness of population-based roll out of human papillomavirus vaccination against rates of genital warts.
    Smith JS; Weiderpass E
    J Natl Cancer Inst; 2013 Apr; 105(7):449-51. PubMed ID: 23486549
    [No Abstract]   [Full Text] [Related]  

  • 5. The incidence of genital warts in Australian women prior to the national vaccination program.
    Brotherton JM; Heywood A; Heley S
    Sex Health; 2009 Sep; 6(3):178-84. PubMed ID: 19653953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in Genital Warts in the Era of Human Papillomavirus Vaccination.
    Calo WA; Brewer NT
    Sex Transm Dis; 2015 Dec; 42(12):669-70. PubMed ID: 26560967
    [No Abstract]   [Full Text] [Related]  

  • 7. Utility of the Human Papillomavirus Vaccination in Management of HPV-associated Cutaneous Lesions.
    Gay J; Johnson N; Kavuru V; Phillips M
    Skin Therapy Lett; 2021 Mar; 26(2):6-8. PubMed ID: 33769773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.
    Petry KU; Bollaerts K; Bonanni P; Stanley M; Drury R; Joura E; Kjaer SK; Meijer CJLM; Riethmuller D; Soubeyrand B; Van Damme P; Bosch X
    Hum Vaccin Immunother; 2018 Jul; 14(7):1800-1806. PubMed ID: 29553886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Number of human papillomavirus vaccine doses and condyloma.
    Kreimer AR; Safaeian M; Hildesheim A
    JAMA; 2014 Jun; 311(23):2439. PubMed ID: 24938569
    [No Abstract]   [Full Text] [Related]  

  • 10. Number of human papillomavirus vaccine doses and condyloma--reply.
    Ploner A; Herweijer E; Arnheim-Dahlström L
    JAMA; 2014 Jun; 311(23):2439-40. PubMed ID: 24938570
    [No Abstract]   [Full Text] [Related]  

  • 11. Promising control of genital warts: but is elimination possible?
    Lacey CJ; Garnett GP
    Lancet Infect Dis; 2011 Jan; 11(1):4-6. PubMed ID: 21183139
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cervix carcinoma--Austrian Vaccination Committee recommends HPV vaccination].
    Six L; Joura EA
    Wien Med Wochenschr; 2007; 157(5-6):130-2. PubMed ID: 17427010
    [No Abstract]   [Full Text] [Related]  

  • 13. [Genital warts and HPV vaccination].
    Pilka R; Dvorák V; Fait T
    Ceska Gynekol; 2011 Dec; 76(6):468-70. PubMed ID: 22312844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of herd immunity from human papillomavirus vaccination.
    Bogaards JA; Berkhof J
    Lancet Infect Dis; 2011 Dec; 11(12):896; author reply 896-7. PubMed ID: 22115067
    [No Abstract]   [Full Text] [Related]  

  • 15. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
    Van de Velde N; Boily MC; Drolet M; Franco EL; Mayrand MH; Kliewer EV; Coutlée F; Laprise JF; Malagón T; Brisson M
    J Natl Cancer Inst; 2012 Nov; 104(22):1712-23. PubMed ID: 23104323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of anogenital warts: epidemiological risk factors and real-life impact of human papillomavirus vaccination.
    Tyros G; Mastraftsi S; Gregoriou S; Nicolaidou E
    Int J STD AIDS; 2021 Jan; 32(1):4-13. PubMed ID: 33167803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure.
    Lurie S; Mizrachi Y; Chodick G; Katz R; Schejter E
    Gynecol Oncol; 2017 Aug; 146(2):299-304. PubMed ID: 28602548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [AN HPV-ASSOCIATED DISEASES AND CERVICAL CANCER AND PROPHYLACTIC HUMAN PAPILLOMAVIRUS (HPV) VACCINES].
    Malinova M
    Akush Ginekol (Sofiia); 2015; 54 Suppl 1():25-31. PubMed ID: 26137767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papillomavirus vaccination and genital warts in young Indigenous Australians: national sentinel surveillance data.
    Ali H; McManus H; O'Connor CC; Callander D; Kong M; Graham S; Saulo D; Fairley CK; Regan DG; Grulich A; Low N; Guy RJ; Donovan B
    Med J Aust; 2017 Mar; 206(5):204-209. PubMed ID: 28301790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of human papillomavirus vaccine in reducing genital warts: A Google Trends analysis.
    Simonart T; Lam Hoai XL; De Maertelaer V
    J Am Acad Dermatol; 2022 Apr; 86(4):956-958. PubMed ID: 33812953
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.